Danube Symposium

2024-04-18 - 2024-05-20
Budapest, Hungary

ASH 2023

2023-12-09 - 2023-12-12
San Diego, United States

ESMO 2023

2023-10-20 - 2023-10-24
Madrid, Spain

ESMO Breast Cancer 2023

2023-05-11 - 2023-05-13
Berlin, Germany

EADO 2023

2023-04-20 - 2023-04-22
Rome, Italy

AACR 2023

2023-04-14 - 2023-04-19
Orlando, United States

SABCS 2022

2022-12-07 - 2022-12-10
Alcobendas, Afghanistan

ESMO 2022

2022-09-09 - 2022-09-13
Paris, France

ASCO 2022

2022-06-03 - 2022-06-07
Chicago, United States
Search in Scientific Content:
Date
Filters:
Breakthrou
4:18

Breakthroughs and challenges in the treatment of head and neck cancer

Presenter: Robert Sifrer
Danube Symposium
HPV-associ
7:16

HPV-associated head and neck cancers

Presenter: Thomas Hoffmann
Danube Symposium
Follicular
12:06

Follicular Lymphoma highlights of the ASH 2023 Congress

Presenter: Carla Casulo
Specialty: Hematology
ASH 2023
Highlights
9:22

Highlights of the ASH 2023 Congress

Presenter: Mikkael Sekeres
Specialty: Hematology
ASH 2023
Present an
14:07

Present and future of Multiple Myeloma management

Presenter: Xavier Leleu
Specialty: Hematology
ASH 2023
Ibrutinib-
5:010

Ibrutinib-Venetoclax Combination Found Effective Against Mantle Cell Lymphoma

Presenter: Michael Wang
Specialty: Hematology
ASH 2023
Real-World
5:20

Real-World Outcomes With Brexucabtagene Autoleucel

Presenter: Swetha Kambhampati
Specialty: Hematology
ASH 2023
Frontline
8:20

Frontline Treatment With Targeted Agents in Patients With Chronic Lymphocytic Leukemia - report from ASH2023

Presenter: Adrian Wiestner
Specialty: Hematology
ASH 2023
Dramatical
6:21

Dramatically Worse Myeloma Outcomes in Real World vs. Trials

Presenter: Alissa Visram
Specialty: Hematology
ASH 2023
Multiple M
10:58

Multiple Myeloma highlights of ASH 2023 Congress

Presenter: Andrzej Jakubowiak
Specialty: Hematology
ASH 2023
Chronic My
12:36

Chronic Myeloid Leukemia highlights of ASH 2023 Congress

Presenter: Giuseppe Saglio
Specialty: Hematology
ASH 2023
Acute myel
4:57

Acute myeloid leukemia highlights of ASH 2023 Congress

Presenter: Eunice S. Wang
Specialty: Hematology
ASH 2023
Chronic My
5:50

Chronic Myeloid Leukemia: Novel Therapeutic Approaches

Presenter: Carmen Fava
Specialty: Hematology
ASH 2023
Non-Hodgki
8:31

Non-Hodgkin Lymphoma highlights of the ASH 2023 Congress

Presenter: Umberto Vitolo
Specialty: Hematology
ASH 2023
Diagnostic
11:52

Diagnostic and Therapeutic Novelties of Multiple Myeloma Management

Presenter: Enrique Ocio
Specialty: Hematology
ASH 2023
Acute myel
4:45

Acute myeloid leukemia highlights of the ASH 2023 Congress

Presenter: Agnieszka Wierzbowska
Specialty: Hematology
ASH 2023
Effects of
11:15

Effects of prolonging adjuvant aromatase inhibitor therapy beyond five years on recurrence and cause-specific mortality: an EBCTCG meta-analysis of individual patient data from 12 randomised trials including 24,912 women

Presenter: Richard Gray
Specialty: Breast Cancer
Alpelisib
14:48

Alpelisib + fulvestrant for advanced breast cancer: Subgroup analyses from the Phase III SOLAR-1 trial

Presenter: Dejan Juric
Specialty: Breast Cancer
Lifestyle
8:40

Lifestyle Intervention Helped Breast Cancer Survivors Lose Weight, and Was Associated with Higher Disease-free Survival Rates

Presenter: Wolfgang Janni
Specialty: Breast Cancer
Choice of
8:39

Choice of Surgery May Affect Quality of Life for Young Breast Cancer Survivors

Presenter: Laura Dominici
Specialty: Breast Cancer
Circulatin
10:32

Circulating Tumor Cell Count Could Help Choose Treatment for Metastatic Breast Cancer Patients

Presenter: Francois-Clement Bidard
Specialty: Breast Cancer
Axillary R
9:45

Axillary Radiotherapy and Lymph Node Surgery Yielded Comparable 10-year Outcomes for Patients with Breast Cancer

Presenter: Emiel J. T. Rutgers
Specialty: Breast Cancer
Accelerate
6:19

Accelerated Partial Breast Irradiation, Although Close, was Not Equivalent to Whole Breast Irradiation To Control Ipsilateral Breast Tumor Recurrence

Presenter: Fank Vicini
Specialty: Breast Cancer
A randomiz
10:32

A randomized placebo controlled phase III trial of low dose tamoxifen for the prevention of recurrence in women with operated hormone sensitive breast ductal or lobular carcinoma in situ

Presenter: Andrea De Censi
Specialty: Breast Cancer
PALLET: A
12:51

PALLET: A neoadjuvant study to compare the clinical and antiproliferative effects of letrozole with and without palbociclib

Presenter: Mitchell Dowsett
Specialty: Breast Cancer
Phase III
9:33

Phase III KATHERINE Clinical Trial Crossed Early Reporting Boundary and Met its Primary Endpoint

Presenter: Charles E. Geyer, Jr
Specialty: Breast Cancer
Adjuvant C
8:05

Adjuvant Capecitabine Did Not Significantly Improve Outcomes for Patients With Early-stage Triple-negative Breast Cancer

Presenter: Miguel Martín
Specialty: Breast Cancer
Adjuvant C
7:33

Adjuvant Chemotherapy Might Not Add Benefit in Breast Cancer Patients who Have Excellent Response to Neoadjuvant Chemotherapy

Presenter: Laura Spring
Specialty: Breast Cancer
Delaying A
5:48

Delaying Adjuvant Chemotherapy Associated With Worse Outcomes for Patients With Triple-negative Breast Cancer

Presenter: Zaida Morante
Specialty: Breast Cancer
Low-Dose T
9:12

Low-Dose Tamoxifen Was Safe and Effective at Reducing Recurrence and New Breast Disease for Patients With DCIS, LCIS, and ADH

Presenter: Andrea De Censi
Specialty: Breast Cancer
Increasing
11:01

Increasing the dose intensity of adjuvant chemotherapy: an EBCTCG meta-analysis

Presenter: Richard Gray
Specialty: Breast Cancer
Phase Ib/I
8:36

Phase Ib/II Study Evaluating Safety and Efficacy of Pembrolizumab and Trastuzumab in Patients with Trastuzumab-Resistant HER2-positive Advanced Breast Cancer: Results from the PANACEA Study (IBCSG 45-13/BIG 4-13/KEYNOTE-014)

Presenter: Sherene Loi
Specialty: Breast Cancer
Overall Su
13:30

Overall Survival Results of KEYNOTE-564

Presenter: Stefan N. Symeonides
Overall Su
20:13

Overall Survival Results of KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma

Presenter: David F. McDermott
ESMO 2023
1:13

ESMO 2023 Scientific Chair's welcome and invitation to next year's ESMO Congress

Presenter: Silke Gillessen
Interrupti
1:17

Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer

Presenter: Matteo Lambertini
The issue
1:15

The issue of adjuvant vs neoadjuvant treatment

Presenter: Paolo A. Ascierto
The treatm
1:19

The treatment sequence in metastatic melanoma

Presenter: Paolo A. Ascierto
Functional
1:19

Functional Precision Medicine in Oncology

Presenter: Anthony Letai
The first
1:10

The first mRNA cancer vaccine with pembrolizumab minimizes recurrence rate in melanoma tells Jeffrey Weber clinical investigator

Presenter: Jeffrey Weber
Paradigm s
12:05

Paradigm shift in the early NSCLC? The role of ICIs in the adjuvant treatment

Presenter: Federico Cappuzzo
How will t
9:43

How will the current therapeutic options change the treatment of RCC in the daily practice?

Presenter: Camillo Porta
The role o
5:58

The role of immune checkpoint inhibitors and VEGF TKIs in the adjuvant treatment of renal cell carcinoma

Presenter: David F. McDermott
Treatment
11:50

Treatment intensification in the treatment of prostate cancer

Presenter: Oliver Sartor
Pembrolizu
16:35

Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma

Presenter: Stefan N. Symeonides
State of t
6:13

State of the art treatment of bladder cancer

Presenter: Matthew R. Zibelman
First-line
7:41

First-line pembrolizumab plus chemotherapy versus chemotherapy in advanced esophageal cancer

Presenter: Ken Kato